Myriad Genetics Presents Strong Precise MRD Test Data from MONSTAR-SCREEN-3
Myriad Genetics announced it will share data demonstrating the utility of its Precise MRD™ (molecular residual disease) test across diverse cancer types through six poster presentations. Interim outcomes from the MONSTAR-SCREEN-3 study showed exceptional performance, with 97% baseline detection and 16% of samples detected in the ultrasensitive range. Importantly, post-surgical ctDNA positivity at one month was strongly prognostic for recurrence risk, indicating significantly worse disease-free survival. The company emphasizes the clear advantage of its whole-genome, personalized MRD approach in detecting clinically meaningful signals at very low ctDNA levels, potentially enabling earlier clinical decision-making.
Key Highlights
- Myriad Genetics to present data on Precise MRD™ test across six poster presentations.
- Interim outcomes from MONSTAR-SCREEN-3 study demonstrate prognostic power of the assay.
- MONSTAR-SCREEN-3 showed 97% baseline detection, with 16% of samples in the ultrasensitive range.
- Post-surgical ctDNA positivity at one month was linked to significantly worse disease-free survival.
- Data highlights the advantage of a whole-genome, personalized MRD approach in capturing low ctDNA levels.
- Other presentations focus on ovarian, gastric, head & neck cancer, and sarcoma.
- Myriad's booth will feature Precise MRD, MyRisk, Prolaris + AI, MyChoice CDx, MSK-ACCESS, and MSK-IMPACT tests.
Price Impact
More from MYGN